Table 1. Frequency of Increased mRNA Expression in SSA/P Signatures Genes in 30 Hypermutated and 165 Non-Hypermutated Colon Cancers from the Cancer Genome Atlas.

Frequency of increased mRNA expression in SSA/P signature genes in hypermutated and non-hypermutated colon cancers (CC) from the Cancer Genome Atlas (TCGA).

Gene Symbol	Gene Description	Hypermutated CC Incidence (%)	Non- Hypermutated CC Incidence (%)	Fisher Exact P-value
FSCN1	Fascin actin-binding protein 1	9 (30)	3 (2)	<0.001
ZIC5	Zic family member 5	7 (23)	5 (3)	<0.001
CRYBA2	Crystallin, beta A2	5 (17)	0 (0)	<0.001
SEMG1	Semenogelin	4 (13)	0 (0)	<0.001
ZIC2	Zic family member 2	6 (20)	4 (2)	0.001
TRNP1	TMF1-regulated nuclear protein 1	6 (20)	5 (3)	0.002
MUC6	Mucin 6	4 (13)	1 (1)	0.002
FOSL1	FOS-like antigen 1	3 (10)	1 (1)	0.012
ALDH1L1	Aldehyde dehydrogenase 1 family member L1	5 (17)	7 (4)	0.022
KLK10	Kallikrein related peptidase 10	3 (10)	4 (2)	0.075
SLC18A1	Solute carrier family 18, member 1	3 (10)	4 (2)	0.075
VNN1	Vanin 1	3 (10)	4 (2)	0.075
MUC17	Mucin 17	3 (10)	13 (8)	0.717
ANXA10	Annexin A10	1 (3)	2 (1)	0.396
CLDN1	Claudin 1	1 (3)	11 (7)	0.696

Incidence of increased mRNA in 195 colon cancers (30 hypermutated and 165 non-hypermutated) was obtained using TCGA data available in the cBioPortal for Cancer Genomics, Memorial Sloan-Kettering Cancer Center. Table lists 13/51 signature genes that show frequent (≥ 10%) increased mRNA expression in hypermutated colon cancers. Incidence of increased mRNA expression are also shown for two previously developed SSA/P gene markers, annexin A10 (ANXA10) and claudin 1 (CLDN1). Changes in mRNA expression were obtained by comparing normalized read counts (RPKM) for each gene across colon cancers diploid for each gene. Statistical significant differences between incidence of increased mRNA expression between hypermutated and non-hypermutated were determined using a Fisher Exact test. Nine genes showed statistically significant increased incidence of mRNA overexpression in hypermutated colon cancers.